In short
BMS-986517 is an investigational protein-based medicine being studied in a first-in-human clinical trial for advanced solid tumors. The trial is a Phase 1/2a study enrolling 58 participants and is currently authorised. It is given by intravenous infusion, either alone or in combination with another investigational medicine.
BMS-986517 is an investigational protein-based substance being developed by Bristol-Myers Squibb International Corporation. It has no marketing authorisation in the product records, meaning it is not yet an approved medicine. The substance is classified under the therapeutic area of neoplasms (cancers).
Key points
- BMS-986517 is an investigational protein-based substance with no marketing authorisation.
- It is being studied in advanced solid tumors in a Phase 1/2a trial.
- The trial plans to enrol 58 participants.
- BMS-986517 is given by intravenous infusion.
- The main goal is to assess safety and dose-limiting toxicities.
- The study is currently authorised.
What is BMS-986517?
BMS-986517 is a protein-based substance of the type "Protein - Other". It is an investigational medicine, which means it is still being tested in clinical trials and has not been approved for use outside of research. The product records list BMS-986517 as the only name for this substance. The company responsible for the product is Bristol-Myers Squibb International Corporation.
How does BMS-986517 work?
The available registry data do not describe the specific mechanism of action of BMS-986517. As a protein-based substance, it belongs to a category of medicines that are typically designed to interact with specific targets in the body, but no further details on how it works are provided in the trial record.
Which conditions is BMS-986517 studied for?
- Advanced solid tumors — cancers that have spread from where they started and are no longer limited to one area.
How is BMS-986517 given?
BMS-986517 is given as a solution for infusion, administered by intravenous use (into a vein). In the trial, it is being tested alone and in combination with another investigational medicine called BNT327, which is also given by intravenous infusion.
What do the clinical trials show?
There is one clinical trial of BMS-986517 in the registry: a Phase 1/2a, first-in-human study in participants with advanced solid tumors. The trial is authorised and plans to enrol 58 participants. The study is divided into two parts: Part 1 aims to find safe doses of BMS-986517 given alone or in combination with an investigational medicine, and Part 2 checks whether the chosen doses continue to be safe for people with specific cancers. The main thing the trial measures is how often side effects called dose-limiting toxicities happen, as well as how often side effects, serious side effects, side effects causing treatment to stop, or deaths occur.
Who can take part in the trial?
The trial is open to participants with advanced solid tumors. Further details about specific inclusion and exclusion criteria are not provided in the registry record.
What side effects are known?
No information on side effects is available from the provided sources. The trial is designed to monitor side effects, including dose-limiting toxicities, serious side effects, and side effects that cause treatment to stop, but no results have been reported yet.